Big Pharma + Big Failure = Big Punishment
Rarely do you see a Big Pharma member worth tens of billions sell off dramatically, but Bristol-Myers Squibb was down more than 8% today. Insider-trading allegations have hit the company, but the real anchor on share prices is the halt of a phase 3 trial for an important drug because of safety concnerns. Find out which drug it was and where Bristol goes from here by watching the video.
Getting a drug approved for Big Pharma or small biotechs like Arena Pharmaceuticals is a tremendous challenge often filled with setbacks. While the future looks bright for Arena, there are still plenty of obstacles ahead. In our brand-new premium research report on Arena Pharmaceuticals, we walk investors through the must-know opportunities and threats facing the company. Since key news can develop quickly, we're also including a full year of updates for those who sign up. Click here now to learn more.
The article Big Pharma + Big Failure = Big Punishment originally appeared on Fool.com.David Williamson holds no position in any company mentioned. Click here to see his holdings and a short bio. Motley Fool newsletter services have recommended buying shares of Gilead Sciences and Vertex Pharmaceuticals. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. Try any of our Foolish newsletter services free for 30 days. The Motley Fool has a disclosure policy.